TG01 is Targovax’s lead RAS immunotherapy product - a peptide based therapeutic anti-cancer vaccine targeted at the difficult to treat RAS mutations found in more than 85% of pancreatic cancer, 50% of colorectal cancer and 20-30% of all cancers. Initially being tested in the clinic in pancreatic cancer, it is hoped that by inducing immune responses in cancer patients with RAS mutations, TG01 will prolong time to cancer progression, increase survival and improve safety and tolerability compared to chemotherapy and other immunotherapies.
TG01 has recently completed a Phase I/II clinical trial in resected pancreatic cancer. TG01 induced immune responses in almost all patients and had a favorable safety and tolerability profile. Encouraging 2 year overall survival data showed that 13 out of 19 patients were still alive after two years (68%). This contrasts favorably with historical 2-year overall survival rates of 30-53%.
TG02, a follow on product candidate, will initiate a Phase Ib clinical trial in colorectal cancer during the second half of 2016.
TG03 is a further immuno-oncology approach in discovery.
These peptide-based targeted immunotherapies are being investigated in RAS-mutated patients across various tumor types including pancreatic cancer, colorectal cancer, lung cancer or malignant melanoma.
Jon Amund Eriksen
Chief Technology Innovation Officer
Even though RAS mutations were identified as key drivers of cancer progression and treatment resistance several decades ago, effective treatments of RAS-mutated cancers have yet to be made available for patients. We hope that our RAS-targeted immunotherapy will be a practice changing cancer treatment approach.
See publications on peptide-based targeted immunotherapies.